ERBB2 and breast cancer: A population-based cohort study of adult women with stage I-III triple negative or HER2-positive BC found that a substantial number of patients do not receive NACT as their first treatment, furthermore, the majority the patients who did not receive NACT, were not assessed by a medical oncologist prior to initial treatment14.